Evidence map›Paper›PMID 31996780›Full record

ArticleScientific reports2020

Influence of MUC5B gene on antisynthetase syndrome.

Raquel López-Mejías, Sara Remuzgo-Martínez, Fernanda Genre, Verónica Pulito-Cueto, Sonia M Fernández Rozas, Javier Llorca, David Iturbe Fernández, Víctor M Mora Cuesta, Norberto Ortego-Centeno, Nair Pérez Gómez and 27 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Defining anti-synthetase syndrome: a systematic literature review.Clinical and experimental rheumatology · 2022
    Pooled it
  2. Review
  3. Journal of clinical medicine · 2024
    Article
  4. Review
  5. A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.International journal of molecular sciences · 2024
    Review
  6. Review
  7. The MUC5B Promoter Polymorphism is Not Associated With Non-ILD Chronic Respiratory Diseases or Post-transplant Outcome.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Article
  8. Article
  9. Single Nucleotide Polymorphism in theLife (Basel, Switzerland) · 2021
    Article
  10. TheFrontiers in medicine · 2021
    Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 17 institutions in 3 countries.

Raquel López-Mejías *Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. rlopezmejias78@gmail.com.ORCID http://orcid.org/0000-0003-0548-2689
Sara Remuzgo-Martínez *Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Fernanda Genre *Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Verónica Pulito-CuetoEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Sonia M Fernández RozasEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Javier LlorcaDepartment of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain.
David Iturbe FernándezEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Víctor M Mora CuestaEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Norberto Ortego-CentenoSystemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain.
Nair Pérez GómezDivision of Rheumatology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Antonio Mera-VarelaDivision of Rheumatology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Julia Martínez-BarrioDepartment of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Francisco Javier López-LongoDepartment of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Verónica MijaresEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Leticia Lera-GómezEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
María Piedad UsettiPneumology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Rosalía LaportaPneumology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Virginia PérezLung Transplant Unit, Division of Pulmonology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Alicia De Pablo GafasLung Transplant Unit, Division of Pulmonology, Hospital Universitario 12 de Octubre, Madrid, Spain.
María Aránzazu Alfranca GonzálezDepartment of Immunology, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain.
Jaime Calvo-AlénRheumatology Division, Hospital Universitario Araba, Universidad del País Vasco, Vitoria, Spain.
Fredeswinda Romero-BuenoRheumatology Department, Bone and Joint Research Unit, Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
Olga Sanchez-PernauteRheumatology Department, Bone and Joint Research Unit, Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
Laura NunoRheumatology Department, Hospital Universitario La Paz, Madrid, Spain.
Gema BonillaRheumatology Department, Hospital Universitario La Paz, Madrid, Spain.
Alejandro BalsaRheumatology Department, Hospital Universitario La Paz, Madrid, Spain.
Fernanda Hernández-GonzálezRespiratory Department, Hospital Clínico de Barcelona, Barcelona, Spain.
Ignacio GrafiaDepartment of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona, Barcelona, Spain.
Sergio Prieto-GonzálezDepartment of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona, Barcelona, Spain.
Javier NarvaezRheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.
Ernesto Trallero-AraguasDepartment of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain.
Albert Selva-O'CallaghanDepartment of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain.
Oreste GualilloServizo Galego de Saude and Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-7154-1328
Santos CastañedaRheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain.
Lorenzo CavagnaDivision of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation of Pavia and ERN ReCONNET, Pavia, Italy.
José M CifrianEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Miguel A González-GayEpidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Instituto de Investigación Marqués de Valdecilla · ESHospital Clínic de Barcelona · ESHospital Universitario La Paz · ESComplejo Hospitalario Universitario de Santiago · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario 12 De Octubre · ESHospital Universitario de La Princesa · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Puerta de Hierro Majadahonda · ESUniversidad de Cantabria · ESUniversitat Autònoma de Barcelona · ESBellvitge University Hospital · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Investigación Sanitaria de Santiago · ESMarqués de Valdecilla University Hospital · ESUniversity of Pavia · ITUniversity of the Basque Country · ES

Funding

EC | Research Executive Agency (REA) 734899Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CP16/00033Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI17/00409Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI18/00042Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) RD16/0012/0009Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) RD16/0012/0014
6 · The paper itself

Abstract

MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.

Indexed as

AdultFemaleFollow-Up StudiesHumansIncidenceLung Diseases, InterstitialMaleMiddle AgedMucin-5BMyositisPolymorphism, Single NucleotidePromoter Regions, GeneticMUC5B protein, humanMucin-5B

Identifiers

PMID31996780
PMCPMC6989632
OpenAlexW3004135039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.